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Abstract
Objective To compare the survival outcomes of patients treated with
surgery or radiotherapy for prostate cancer.
Design Observational study.
Setting Sweden, 1996-2010.
Participants 34 515 men primarily treated for prostate cancer with
surgery (n=21 533) or radiotherapy (n=12 982). Patients were categorised
by risk group (low, intermediate, high, andmetastatic), age, and Charlson
comorbidity score.
Main outcome measures Cumulative incidence of mortality from
prostate cancer and other causes. Competing risks regression hazard
ratios for radiotherapy versus surgery were computed without adjustment
and after propensity score and traditional (multivariable) adjustments,
as well as after propensity score matching. Several sensitivity analyses
were performed.
Results Prostate cancer mortality became a larger proportion of overall
mortality as risk group increased for both the surgery and the
radiotherapy cohorts. Among patients with non-metastatic prostate
cancer the adjusted subdistribution hazard ratio for prostate cancer
mortality favoured surgery (1.76, 95% confidence interval 1.49 to 2.08,
for radiotherapy v prostatectomy), whereas there was no discernible
difference in treatment effect among men with metastatic disease.
Subgroup analyses indicated more clear benefits of surgery among
younger and fitter men with intermediate and high risk disease. Sensitivity
analyses confirmed the main findings.
Conclusions This large observational study with follow-up to 15 years
suggests that for most men with non-metastatic prostate cancer, surgery
leads to better survival than does radiotherapy. Younger men and those
with less comorbidity who have intermediate or high risk localised
prostate cancer might have a greater benefit from surgery.
Introduction
Prostate cancer is the commonest non-dermatological cancer
and the second leading cause of cancer related death in men in
the Western world.1 In more than 90% of cases the cancer is
localised, and radical prostatectomy, radiotherapy, and active
surveillance represent themain treatment options.2The landmark
Scandinavian Prostate Cancer Group (SPCG)-4 trial3 has shown
a definite survival advantage for surgery over watchful waiting,
at a median follow-up of 12.8 years, although the more recent
randomised controlled trial, the Prostate Intervention Versus
Observation Trial (PIVOT),4 has indicated that the benefit from
surgerymight be confined to intermediate and high risk tumours.
Only one recent randomised controlled trial examined the
comparative effectiveness of different treatment modalities, the
ProtecT study,5 the results of which will not be available for at
least the next two years. Furthermore, the results of randomised
controlled trials may have limited generalisability because of
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differences between the enrolled population and community
populations, who are likely to be more heterogeneous for
comorbidities and socioeconomic characteristics.6 Hence the
importance of using observational data from actual medical
practice in comparative effectiveness studies to complement
the evidence from randomised controlled trials. In the specialty
of prostate cancer, however, most such studies have evaluated
biochemical recurrence as the endpoint, and have shown
conflicting results.7 8 The definition of biochemical recurrence
varies between surgical and radiotherapy cohorts, and even
between individual radiotherapy series, and thus comparing
biochemical recurrence across treatment modalities is
problematic. Furthermore, the median time to death after
biochemical recurrence has been shown to be as long as 13 years
in a surgical series,9 and not all men who experience recurrence
will develop clinical disease. Hence, death remains the most
valid endpoint for comparative studies in prostate cancer.
In this nationwide population based cohort study we assessed
prostate cancer related mortality in patients in the Swedish
national prostate cancer registry, who underwent radical
prostatectomy or radiotherapy as their primary treatment.
Linkage with other healthcare and demographic databases
enabled reduction of potential confounding through statistical
techniques as well as adjustment for competing risks of
mortality, as many men with prostate cancer are known to die
of other causes.10 We hypothesised that survival differences
would vary by treatment, and that age and the burden from
comorbidities would have an impact on survival.
Methods
This study is based on the PCBaSe Sweden, which has been
described previously.11 12 Briefly, it is a composite population
based dataset of the National Prostate Cancer Registry of
Sweden, the Swedish cancer register, the cause of death register,
and six other national registers, using the unique 10 digit
personal identity number assigned to every resident in Sweden.
The dataset covers 98% of all cases of prostate cancer in Sweden
diagnosed since 1998 (with coverage from 1996 and 1997
limited to certain regions), and has virtually complete data on
year of diagnosis; age; clinical stage (tumour, node, metastases
(TNM) classification); tumour grade (either Gleason sum or
World Health Organization grade of differentiation); serum
level of prostate specific antigen at the time of diagnosis;
planned primary treatment within six months of diagnosis;
county of residence; marital status; educational level;
socioeconomic status; Charlson comorbidity index; and cancer
related events during follow-up. The Charlson score was
estimated from registrations in the inpatient register, which in
a previous study based on the PCBaSe dataset has been shown
to have an impact on management and survival.13
We identified a total of 109 333men with a diagnosis of prostate
cancer between 1996 and 2010 in PCBaSe Sweden. After
exclusion of those whose treatment was unknown (n=4788) or
who had died before treatment (n=512), we included all patients
provided their primary treatment was listed as radical
prostatectomy or radiotherapy (n=34 515). From this analysis
we excluded patients who received androgen deprivation or
surgical castration as their primary treatment (n=40 502), or
watchful waiting (n=29 016). The median follow-up time for
the included cohort was 5.37 years (interquartile range 3.00-7.81
years), for the radical prostatectomy group 5.26 (3.03-7.57)
years, and for the radiotherapy group 5.60 (2.96-8.18) years.
As in previous studies using this dataset,11-13 we categorised
patients by clinical risk (low, intermediate, or high risk
(collectively, non-metastatic prostate cancer), and metastatic
disease, table 1⇓), as well as by age (≤64, ≥65) and Charlson
comorbidity index (0, ≥1). After stratification by risk group,
the study cohort comprised 34 052 cases; 463/34 515 (1.3%)
patients had missing data precluding risk categorisation. We
merged WHO grade 1 tumours with Gleason scores 2-6, WHO
2 with Gleason score 7, and WHO 3 with Gleason scores 8-10.
The primary outcome of interest was death from prostate cancer.
We defined survival time as the interval between date of
diagnosis of prostate cancer and the date of death, emigration,
or end of follow-up at 31 December 2010.
Statistical analysis
We used χ2 and Wilcoxon-Mann-Whitney tests to investigate
differences in the distributions of patient characteristics by
treatment groups. To visualise cause specific mortality, we
plotted cumulative incidence curves for the treatment groups.
We investigated differences in each cause of mortality (prostate
cancer or other causes) using subdistribution hazard ratios
estimated through Fine and Gray proportional hazards
regression.14 To deal with any imbalances in the distribution of
covariates among treatment groups, we produced both traditional
multivariable model adjusted and propensity score adjusted
estimates of subdistribution hazard ratios. We calculated
propensity scores using logistic regression, with treatment group
as outcome and all adjustment covariates as predictors; wemade
adjustments by including the resulting logit transformed
propensities when modelling subdistribution hazard ratios. We
tested heterogeneity of such ratios across risk groups using
likelihood ratio tests of the relevant interaction terms.
Furthermore, we used the propensity scores for matching, which
we carried out within each risk group, using the larger of the
two treatment groups and selecting a nearest neighbour 1-to-1
match for those in the smaller treatment group, with a caliper
of 0.1 standard deviations for the propensity scores.
We carried out several sensitivity analyses. Assuming that the
cancer treatment resulted in no difference in prostate cancer
mortality, we assessed the effect required of a hypothetical
unmeasured binary confounder to explain the propensity score
adjusted subdistribution hazard ratios for prostate cancer
mortality of radiotherapy versus radical prostatectomy for
varying levels of confounder imbalance between treatment
groups.15 16 To investigate possibly divergent developments in
treatment efficiency we reassessed the comparisons after
stratification by year of diagnosis (1996-99, 2000-04, and
2005-09). Furthermore, we used the propensity scores for inverse
probability of treatment weight adjustments; we carried out
these through weighting data from each individual with weights
proportional to the estimated propensity of the treatment not
received, using Cox proportional hazards regression.
All tests were performed two sided at the 5% significance level.
Statistical analyses were performed with IBM SPSS Statistics
(version 20.0, IBM, Armonk, NY), and R software (version
2.15, R Foundation for Statistical Computing, Vienna, Austria)
using the cmprsk, survival, rmeta, and Matching packages.
Results
Table 2⇓ shows the baseline clinical and tumour characteristics
of the participants, stratified by treatment. Generally, the
radiotherapy group had a greater proportion of high clinical
stage and grade disease, with higher levels of prostate specific
antigen than the radical prostatectomy group. This was also the
case within each individual risk group. Patients who received
radiotherapy were on average also older and had higher scores
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on the Charlson comorbidity index. Patients in the radical
prostatectomy group on average received their diagnosis at a
later date than patients in the radiotherapy group. Furthermore,
the choice of treatment differed significantly by county of
residence (data not shown), and the radiotherapy group had a
greater proportion of patients of low educational level, low
socioeconomic status, and unmarried status. In each
non-metastatic risk group the demographic and clinical
characteristics of the patients showed the same differences when
stratified by treatment modality, albeit attenuated for the tumour
covariates (as a result of the risk categorisation). In the
metastatic risk group, some adverse prognostic criteria such as
a higher Charlson comorbidity score, N+ stage, and M+ stage,
were more common in the radical prostatectomy group, whereas
others were more common in the radiotherapy cohort. By the
end of the study, 339 prostate cancer related deaths and 1064
deaths from other causes occurred in the radical prostatectomy
arm and 697 and 1127, respectively in the radiotherapy arm
(table 3⇓).
The mortality estimates in the radical prostatectomy group were
lower for non-metastatic disease (risk groups 1-3) than in the
radiotherapy group (fig 1⇓). This was the case for mortality
from both prostate cancer and other causes, although as clinical
risk increased prostate cancer related mortality became a larger
proportion of the overall mortality. In metastatic cases (risk
group 4), roughly half of all the men had died by 15 years, and
over half of those deaths were due to prostate cancer, regardless
of treatment type.
Amongmenwith non-metastatic prostate cancer, treatment with
radiotherapy was associated with a significantly higher crude
prostate cancer mortality than surgery (subdistribution hazard
ratio 3.09, 95% confidence interval 2.69 to 3.56; table 3). Both
propensity score and traditional adjustment reduced the
subdistribution hazard ratios consistently, but results remained
in favour of surgery (1.76, 1.49 to 2.08 and 1.77, 1.49 to 2.09,
respectively); the subdistribution hazard ratios for radiotherapy
versus surgery did not differ significantly between risk groups
(P for homogeneity, 0.17). Differences in survival outcomes
were non-discernible between treatment modalities for patients
with metastatic disease (crude subdistribution hazard ratio 1.04,
95% confidence interval 0.74 to 1.48; table 3); lack of difference
persisted even after the main statistical adjustments. Figure 2⇓
is a forest plot examining whether surgery or radiotherapy leads
to improved survival with prostate cancer, based on risk group,
age, and Charlson comorbidity index, and after adjustment for
propensity score. Among men without metastatic disease, the
subdistribution hazard ratios consistently favoured radical
prostatectomy over radiotherapy, with point estimates for
surgery trending to be better in younger men (<65 years) and
fitter (Charlson score 0) men with intermediate (risk group 2)
and high risk (risk group 3) prostate cancer; no discernible
differences can be seen between treatment modalities for patients
with metastatic disease. Similar results to those in figure 2 were
obtained after traditional (multivariable) adjustment (data not
shown). Propensity score matching also confirmed our main
findings of cancer outcomes favouring surgery over radiotherapy
for patients without metastatic prostate cancer with no significant
differences for the metastatic group, albeit with attenuated point
estimates (table 4⇓).
Men without metastatic prostate cancer had lower survival from
other causes of death after radiotherapy (crude subdistribution
hazard ratio 1.77, 95% confidence interval 1.62 to 1.93, table
3). After propensity score and traditional adjustments the results
moved in the direction of the null but remained worse after
radiotherapy (subdistribution hazard ratio 1.32, 95% confidence
interval 1.18 to 1.42 and 1.28, 1.16 to 1.42, respectively). In
men with metastatic prostate cancer, no differences were seen
in other cause mortality between treatments with and without
the main statistical adjustments. Again, these results were
confirmed in the propensity score matched analyses (table 4).
Sensitivity analysis on the non-metastatic groups showed that
the required subdistribution hazard ratio effect of an unmeasured
confounder would have to be large (and in some cases, infinite),
given varying the differential expression of the unmeasured
confounder between the surgery and radiotherapy groups (always
assuming higher confounder levels in the radiotherapy group),
to produce the observed subdistribution hazard ratios for
radiotherapy versus radical prostatectomy (table 5⇓). Analyses
stratified by year of diagnosis showed no discernible temporal
trend in point estimates for treatment comparisons for any risk
groups (see appendix 1 on bmj.com). Furthermore, inverse
probability of treatment weight adjustments showed that cancer
outcomes favoured surgery over radiotherapy for patients
without metastatic prostate cancer, with no significant
differences for the metastatic group, but as with the propensity
score matched sample, the point estimates were attenuated (see
appendix 2 on bmj.com).
Discussion
In this observational study in men treated primarily with either
radical prostatectomy or radiotherapy, with follow-up to 15
years, we found that surgery was associated with better cancer
specific survival than radiotherapy among men with
non-metastatic prostate cancer. Younger and fitter men (those
with fewer comorbidities) and those with higher risk disease
might possibly have the greatest differential benefit with surgery.
We found little if any difference in outcome between treatment
modalities for men with metastatic prostate cancer in our main
analyses, although sensitivity analyses indicated a possible
benefit for radiotherapy. Deaths from other causes seemed to
be worse after radiotherapy for menwith non-metastatic prostate
cancer, but no differences were seen for those with metastatic
prostate cancer.
Comparison with other studies
Other investigators have also examined the comparative
effectiveness of surgery versus radiotherapy inmenwith prostate
cancer. Recently, the Prostate Cancer Results Study Group
compared radical prostatectomy, radiotherapy, cryotherapy, and
high intensity focused ultrasonography, but interpretation of
their results is difficult owing to multiple study limitations,
including the use of differing definitions of biochemical
recurrence as the endpoint.7 One study used the American
Society for Radiation Oncology definition of biochemical
recurrence in 1872 patients treated by surgery, external beam
radiotherapy, or brachytherapy, and found that surgery was
superior in the group with Gleason 8-10 scores, but with no
differences seen for low risk patients in whom follow-up was
relatively short; thus this last cohort did well for cancer outcome
regardless of treatment choice.8 Using clinical recurrence
(metastases) as an endpoint, a study of 2380 patients again
showed that low risk patients had few events and thus no
differences between surgery and radiotherapy were observed,
but for intermediate and high risk patients the data favoured
radical prostatectomy (overall hazard ratio 0.35 for surgery v
radiotherapy).17 Data from an observational study of more than
404 000 men treated at more than 1000 community hospitals
in 44 states of the United States from the Nationwide Inpatient
Sample making up more than 20% of all community hospital
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admissions, including Medicare, Medicaid, uninsured, and
private patients, suggested that surgery had superior cancer
specific and other cause mortality outcomes for men aged less
than 80 years with low and intermediate risk disease.18 19 A
multi-institutional US study of 10 429men treated with surgery,
external beam radiotherapy, or brachytherapy showed that
external beam radiotherapy was associated with an adjusted 10
year prostate cancer specific mortality hazard ratio of 1.5
compared with surgery, but that brachytherapy and surgery were
equivalent.20 Furthermore, a study of 6849 patients from the
primary data source used in our study, the National Prostate
Cancer Registry of Sweden, found that the difference between
observed and expected mortality was greater for surgery
compared with observation than for radiotherapy compared with
observation.21 A study that analysed the Cancer of the prostate
Strategic Urologic research Endeavor database on 7538 men
with high risk prostate cancer found a roughly twofold increase
in cancer specific mortality for radiotherapy compared with
surgery.22 Furthermore, data on 6692menwithout comorbidities
treated from 1995 to 2007 at two academic centres in the United
States showed that radiotherapy was associated with an increase
in prostate cancer related deaths compared with radical
prostatectomy (hazard ratio 1.66).23 Finally, a cohort of 68 665
men with localised prostate cancer treated by surgery or
radiotherapy from 1992-2005 showed that the surgical group
fared substantially better in terms of prostate cancer mortality,
although this study, as with many of the others discussed here,
was limited by the quality of the dataset (Surveillance,
Epidemiology and End Results (SEER)/Medicare) used; the
SEER registry represents only 14% of the US population before
2000 and 26% thereafter, and the Medicare insurance linked
programme only captures those aged 65 or more; missing data
and lack of important covariates is also prevalent.16
A comparative analysis of 1238 patients with high risk disease
who underwent surgery—344 who had external beam
radiotherapy plus hormones, and 265 who received external
beam radiotherapy alone—again showed improved mortality
outcomes in the surgical cohort.24 Our study further supports
that men with high risk disease fared better after surgery, with
statistically significant improvements over radiotherapy in men
aged less than 65 and those without comorbidity. We found no
significant differences between treatments in high risk cases in
older patients or those with comorbidities, and the Nationwide
Inpatient Sample study found that the only subgroup in which
radiotherapy fared better was those aged more than 80 with high
risk disease. Our study included only small numbers of older
men and those with Charlson scores of 1 or more who had high
risk disease, and thus lack of a statistically significant benefit
for radiotherapy might be due to low power. In the absence of
randomised head to head comparisons between surgery and
radiotherapy, we would therefore conclude that for men with
non-metastatic prostate cancer where radical treatment is
indicated, current collective evidence supports surgery as initial
treatment in improving mortality outcomes in younger and fitter
men (those with fewer comorbidities) with intermediate or high
risk disease who are, at the outset, more likely to die of prostate
cancer; older men and those with comorbidities are likely to
fare as well, if not better, with upfront radiotherapy.
We also evaluated mortality outcomes in men with metastatic
prostate cancer who underwent surgery or radiotherapy as their
initial treatment option. We found no statistically significant
differences between the two treatment groups, regardless of age
or Charlson comorbidity index subgrouping in our main
analyses. Our inverse probability of treatment weight analysis
compared two hypothetical groups of surgical and radiotherapy
patients, both cohorts having characteristics with similar
distributions as those of the combined group of all included
surgical and radiotherapy patients. Hence, this analysis allows
a comparison of the situation where all patients received surgery
with the situation where all patients received radiotherapy. In
this supplementary analysis, radiotherapy was associated with
significantly decreased prostate cancer related mortality (hazard
ratio 0.54, 95% confidence interval 0.39 to 0.74). Importantly,
although this group contained the smallest sample sizes,
especially after substratification, we have no knowledge of
secondary or tertiary treatments that may have affected outcome
in these patients. Plus, this grouping was heterogeneous,
including men with limited nodal disease on the one hand and
multimetastatic disease on the other. It is therefore hypothesis
generating rather than hypothesis testing. Another analysis using
the national prostate cancer registry showed that treatment with
curative intent decreased cancer specific mortality noticeably
compared with palliative only treatment in men with presenting
prostate specific antigen concentrations of 51-100 ng/mL (hazard
ratio 0.22).25 Hence, although radical treatment might have a
role in this patient population, our data do not favour one
primary treatment over the other.
Our study showed that themajority of menwith low risk prostate
cancer did not die of prostate cancer within 15 years of
follow-up. The recent PIVOT study, which randomly assigned
731 men with localised prostate cancer to radical prostatectomy
or to observation found no benefit for surgery in men with low
risk disease at a median follow-up of 10 years.4 The SPCG-4
trial showed that the benefit of surgery over watchful waiting
continued to be seen beyond nine years, with the recent update
(median 12.8 years of follow-up) showing larger improvements
in survival associated with surgery.3 Benefit was seen in those
with low risk disease as well, although it was greater in those
with higher risk and was confined to men aged less than 65
years. Cumulatively, these two randomised controlled trials
suggest that radical treatment is more beneficial in younger men
and in those with intermediate and high risk tumours, since
these men are at the highest risk of dying from prostate cancer.
Competing risks models based on the SPCG-4 trial suggested
that surgery was unequivocally of benefit over watchful waiting
inmenwith Gleason 8 or Gleason 7, T2 disease.26These findings
are consistent with our analyses showing more deaths from
prostate cancer in those with intermediate and high risk disease
(fig 1); in such men with longer life expectancies at the outset
(younger men and those with fewer comorbidities) the
differential benefit for surgery over radiotherapy might also be
greater (fig 2). However, it can also be seen that the absolute
numbers of men dying from prostate cancer is still substantial
in the low risk cohort, suggesting that treatment may still be
warranted, at least for some (table 3). Our study also shows, as
in another recent study,27 that to show differential outcomes
from prostate cancer mortality, follow-up of at least 10 years
(and even longer in low risk cases) is required.
Strengths and limitations of this study
Our study has several strengths; it is based on a large, population
based dataset obtained by linking nine national registries in
Sweden, and provides more than 98% complete data collection
of prostate cancer cases at the time of diagnosis and during
follow-up, with their important and highly validated
patient-tumour covariates including comorbidity status. The
reliability of the Swedish cause of death register for correct
assignment of cause of death among patients with prostate
cancer has also been shown to be high.28 Follow-up in this study
was also long, and thus differences in mortality beyond 10 years
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since diagnosis and treatment were captured. Furthermore, we
utilised well described statistical methodology to adjust for
differences in the distribution of covariates between surgical
and radiotherapy cohorts and to account for competing risks of
mortality. Both propensity score and traditional adjustments led
to similar results (table 3), further confirmed by propensity score
matching (table 4) and an inverse probability of treatment weight
sensitivity analysis (see appendix 2 on bmj.com); none the less,
even sophisticated statistical techniques cannot completely
eliminate the biases associated with observational studies, such
as confounding by indication,6 29 and our finding of differences
in non-prostate cancer mortality between treatments after
adjustment might suggest this, especially as the radiotherapy
group had poorer prognosis at baseline. Although there is
evidence that radiotherapy for prostate cancer increases the
incidence of secondary cancers in the longer term,30 31 and that
the accompanying androgen deprivation treatment increases the
risk of diabetes and cardiovascular disease,32 a recent
meta-analysis evaluating 4141 patients from eight randomised
trials found that cardiovascular death rates were not significantly
different between the androgen deprivation treatment and control
groups33; hence, residual confounding is likely to be at least
contributory to our main study findings, as it was in the National
Prostate Cancer Registry Follow-up Study that used the same
primary dataset.21 Hence, we performed a sensitivity analysis
on the non-metastatic groups where differences in outcomes
were seen, and showed that the effect of any unmeasured
confounder would have to be large to infinite to account for our
observed findings (table 5), making it highly unlikely that our
results are completely due to residual confounding. As our study
started before the Gleason system was fully introduced in
Sweden, some of the earlier cases were graded according to the
WHO system and were not regraded for this study; also, no
information was available on tumour extent in core biopsy
specimens, serum prostate specific antigen levels after the date
of diagnosis, actual treatment received, or secondary or later
treatments. Information on radiotherapy dosing or type, or
surgical technique was not available and thus we do not know
how comparable these evaluated treatments are to contemporary
practice, especially with the advent of intensity modulated
radiotherapy, dose escalation programmes, high dose
brachytherapy, and robotic assisted radical prostatectomy. For
instance, it is not known whether radiotherapy dosing levels
over this period in Sweden reached the acceptable contemporary
standard of 74 Gy or more for low risk disease and 78 Gy for
intermediate and high risk cases.34 This might have affected the
results, and is likely to be a much more important confounder
than advances in surgical practice over the years captured in
this study. However, we did a further sensitivity analysis
evaluating comparisons stratified by year of diagnosis (see
appendix 1 on bmj.com) and found no temporal trend in results,
suggesting that a presumed increase in radiotherapy dosing with
time did not significantly confound our findings. No information
is also available from PCBaSe as to whether secondary
treatments were applied, and it might be that a greater proportion
of men in the surgery arm underwent multimodality therapy
than in the radiotherapy arm, because giving radiotherapy after
surgery is more often done than performing surgery after
radiotherapy. This would again bias our findings in favour of
surgery. Also, the Swedish data overwhelmingly constitute
white men and represent a non-screen diagnosed population;
hence, how the findings relate to screen diagnosed men of
various ethnicities in other countries is uncertain. Finally,
treatment choices for men with prostate cancer and their doctors
must take account of toxicity profiles as well as cancer
outcomes, and such data were not available in this study.
Conclusions and policy implications
Notwithstanding these limitations, and in the absence of
prospective, randomised controlled trials, our study suggests
that surgery might result in improved outcomes compared with
radiotherapy in terms of survival for men with non-metastatic
prostate cancer, and that radiotherapy seems at least equivalent,
and may be superior, to surgery for men with metastatic disease.
Given the important burden that prostate cancer poses on the
National Health Service and healthcare systems worldwide,
these findings could have important policy implications for the
allocation of resources in the management of this disease.
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What is already known on this topic
High quality evidence comparing cancer outcomes after surgery and radiotherapy in men with prostate cancer is lacking
Many observational datasets do not have accurate and complete data recording with sufficient follow-up making these comparative
effectiveness studies subject to bias
What this study adds
The majority of men with clinically localised prostate cancer might benefit more from surgery than radiotherapy, whereas radiotherapy
might be preferable in men with metastatic disease
Younger men and those with fewer comorbidities who have intermediate or high risk localised prostate cancer might have a greater
benefit from surgery
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Tables
Table 1| Definition of prostate cancer risk groups used in this study (adapted from PCBaSe Sweden)11 12
Biopsy GleasonProstate specific antigen (ng/mL)Clinical stageRisk categories
≤6 or WHO 1≤10T1-2 N0/Nx M0/MxGroup 1 (low risk)
7 or WHO 210-20Group 2 (intermediate risk)
≥8 or WHO 320-50T3 N0/Nx M0/MxGroup 3 (high risk)
—>50T4 N+ M+Group 4 (metastatic)
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Table 2| Baseline clinicopathological and follow-up data for cohort stratified by treatment type (radical prostatectomy or radiotherapy) and
risk group. Values are numbers (percentages) unless otherwise stated
Risk group 4 patientsRisk group 3 patientsRisk group 2 patientsRisk group 1 patientsAll patients
Variables
Radiotherapy
(n=817)
Surgery
(n=389)
Radiotherapy
(n=5040)
Surgery
(n=2609)Radiotherapy (n=4030)
Surgery
(n=8125)
Radiotherapy
(n=3039)
Surgery
(n=10 003)
Radiotherapy
(n=12 982)
Surgery
(n=215 33)
4.90
(2.51-8.18)
4.97
(2.78-7.21)
5.76
(3.06-8.38)
5.16
(2.90-7.90)
5.22 (2.70-7.95)4.97
(2.73-7.35)
5.89
(3.52-8.21)
5.64
(3.37-7.67)
5.60
(2.96-8.18)
5.26
(3.03-7.57)
Median (IQR)
follow-up time
(years)
0.314<0.0010.004<0.001<0.001P value
2004
(2000-08)
2005
(2002-07)
2004
(2001-07)
2005
(2002-07)
2005
(2002-08)
2005 (2003-08)2004
(2002-07)
2005
(2003-07)
2004
(2001-07)
2005
(2003-07)
Median (IQR)
year of
diagnosis
0.397<0.001<0.001<0.001<0.001P value
65 (60-69)64 (59-68)66 (62-70)64 (60-67)67
(63-71)
63 (59-67)65 (60-69)62 (57-65)66 (62-70)62 (58-66)Median (IQR)
age at
diagnosis
0.003<0.001<0.001<0.001<0.001P value
60.0
(51.0-77.1)
18.6
(8.9-59.0)
19.0 (9.4-28.0)14.0
(7.2-24.0)
11.0 (7.2-14.0)9.9 (6.0-13.0)6.4 (5.0-8.0)5.9
(4.4-7.5)
10.9 (6.8-20.0)7.0
(5.0-11.0)
Median (IQR)
PSA (ng/mL)
<0.001<0.001<0.001<0.001<0.001P value
Clinical stage:
162 (19.9)129 (34.6)977 (19.5)996 (38.6)1907 (47.9)4659 (57.8)1887 (62.9)6895 (69.7)4962 (38.6)12 892
(60.7)
cT1
267 (32.8)157 (42.1)1453 (29.0)947 (36.7)2076 (52.1)3399 (42.2)1112 (37.1)3000 (30.3)4928 (38.3)7613 (35.9)cT2
352 (43.3)76 (20.4)2583 (51.5)640 (24.8)00002935 (22.8)716 (3.4)cT3
32 (3.9)11 (2.9)00000032 (0.2)11 (0.1)cT4
<0.001<0.001<0.001<0.001<0.001P value
N stage:
677 (82.9)171 (44.0)5040 (100.0)2609
(100.0)
4030 (100.0)8125 (100.0)3039 (100.0)10 003
(100.0)
12 842 (98.9)21 315
(99.0)
cN0/Nx
140 (17.1)218 (56.0)000000140 (1.1)218 (1.0)cN1
<0.0010.558P value
M stage:
768 (94.0)342 (87.9)5040 (100.0)2609
(100.0)
4030 (100.0)8125 (100.0)3039 (100.0)10 003
(100.0)
12933 (99.6)21 486
(99.8)
cM0/MX
49 (6.0)47 (12.1)00000049 (0.4)47 (0.2)cM1
<0.0010.007P value
Gleason or
WHO stage:
158 (19.5)113 (29.4)1253 (24.9)651 (25.1)1237 (30.7)2432 (29.9)3039 (100.0)10 003
(100.0)
5700 (44.1)13 393
(62.7)
≤6 or WHO 1
407 (50.2)162 (42.1)1978 (39.4)667 (25.7)2793 (69.3)5693 (70.1)005192 (40.2)6573 (30.8)7 or WHO 2
245 (30.2)110 (28.6)1794 (35.7)1280 (49.3)00002039 (15.8)1390 (6.5)≥8 or WHO 3
0.001<0.0010.389<0.001P value
Charlson
comorbidity
index:
651 (79.7)293 (75.3)3813 (75.7)2068 (79.3)2904 (72.1)6765 (83.3)2275 (74.9)8363 (83.6)9685 (74.6)17 679
(82.1)
0
106 (13.0)40 (10.3)771 (15.3)348 (13.3)719 (17.8)900 (11.1)512 (16.8)1092 (10.9)2115 (16.3)2417 (11.2)1
45 (5.5)33 (8.5)306 (6.1)152 (5.8)266 (6.6)347 (4.3)162 (5.3)420 (4.2)783 (6.0)1070 (5.0)2
15 (1.8)23 (5.9)150 (3.0)41 (1.6)141 (3.5)113 (1.4)90 (3.0)128 (1.3)399 (3.1)367 (1.7)≥3
<0.001<0.001<0.001<0.001<0.001P value
Marital status:
578 (70.7)275 (70.7)3669 (72.8)1964 (75.3)2870 (71.2)5989 (73.7)2177 (71.6)7515 (75.1)9329 (71.9)16 033
(74.5)
Married
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Table 2 (continued)
Risk group 4 patientsRisk group 3 patientsRisk group 2 patientsRisk group 1 patientsAll patients
Variables
Radiotherapy
(n=817)
Surgery
(n=389)
Radiotherapy
(n=5040)
Surgery
(n=2609)Radiotherapy (n=4030)
Surgery
(n=8125)
Radiotherapy
(n=3039)
Surgery
(n=10 003)
Radiotherapy
(n=12 982)
Surgery
(n=215 33)
36 (4.4)18 (4.6)214 (4.2)94 (3.6)186 (4.6)272 (3.3)120 (3.9)266 (2.7)563 (4.3)663 (3.1)Widower
119 (14.6)59 (15.2)707 (14.0)325 (12.5)660 (16.4)1178 (14.5)470 (15.5)1361 (13.6)1967 (15.2)2987 (13.9)Divorced
84 (10.3)37 (9.5)450 (8.9)225 (8.6)314 (7.8)684 (8.4)272 (9.0)861 (8.6)1123 (8.7)1847 (8.6)Single
0.9690.089<0.001<0.001<0.001P value
Educational
level:
199 (24.5)109 (28.1)1138 (22.7)744 (28.7)972 (24.3)2334 (28.9)771 (25.5)3155 (31.6)3093 (24.0)6457 (30.1)High
319 (39.2)149 (38.4)1869 (37.3)1007 (38.9)1579 (39.5)3296 (40.8)1204 (39.8)4080 (40.9)4993 (38.7)8687 (40.5)Intermediate
295 (36.3)130 (33.5)2002 (40.0)839 (32.4)1451 (36.3)2458 (30.4)1047 (34.6)2735 (27.4)4815 (37.3)6296 (29.4)Low
0.375<0.001<0.001<0.001<0.001P value
Socioeconomic
status:
404 (50.3)220 (57.1)2574 (51.6)1450 (56.4)2101 (52.6)4557 (56.7)1579 (52.5)5570 (56.3)6689 (52.1)12 023
(56.5)
White collar
399 (49.7)165 (42.9)2416 (48.4)1121 (43.6)1893 (47.4)3481 (43.3)1428 (47.5)4320 (43.7)6161 (47.9)9262 (43.5)Blue collar or
unemployed
0.027<0.001<0.001<0.001<0.001P value
IQR=interquartile range; PSA=prostate specific antigen; WHO=World Health Organization.
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Table 3| Mortality figures and crude, propensity score adjusted and traditionally adjusted subdistribution hazard ratios (sHR) for radiotherapy
versus radical prostatectomy for deaths from prostate cancer and other causes, stratified by risk group
Radiotherapy versus surgeryNo of events/Total No (%)
Cause of death by
risk group P value
Traditional covariate
adjusted sHR (95%
CI)P value
Propensity score
adjusted sHR (95%
CI)P value
Crude sHR (95%
CI)SurgeryRadiotherapy
Risk group 1:
0.0072.03 (1.22 to 3.40)0.0111.91 (1.16 to 3.14)<0.0012.16 (1.37 to 3.42)44/10 003 (0.4)32/3039 (1.1)Prostate cancer
0.0191.24 (1.04 to 1.48)0.0131.26 (1.05 to 1.51)<0.0011.67 (1.42 to 1.97)412/10 003 (4.1)223/3039 (7.3)Other causes
Risk group 2:
<0.0011.77 (1.36 to 2.30)<0.0011.77 (1.37 to 2.29)<0.0011.95 (1.53 to 2.47)131/8125 (1.6)142/4030 (3.5)Prostate cancer
<0.0011.40 (1.19 to 1.64)<0.0011.43 (1.23 to 1.68)<0.0011.94 (1.68 to 2.24)365/8125 (4.5)376/4030 (9.3)Other causes
Risk group 3:
<0.0011.63 (1.28 to 2.06)<0.0011.50 (1.19 to 1.88)<0.0011.69 (1.38 to 2.07)118/2609 (4.5)418/5040 (8.3)Prostate cancer
0.0911.20 (0.97 to 1.48)0.0811.20 (0.98 to 1.48)<0.0011.42 (1.18 to 1.70)154/2609 (5.9)458/5040 (9.1)Other causes
Non-metastatic (risk
groups 1-3):
<0.0011.77 (1.49 to 2.09)<0.0011.76 (1.49 to 2.08)<0.0013.09 (2.69 to 3.56)293/20 737 (1.4)592/12 109 (4.9)Prostate cancer
<0.0011.28 (1.16 to 1.42)<0.0011.32 (1.18 to 1.47)<0.0011.77 (1.62 to 1.93)931/20 737 (4.5)1057/12 109 (8.7)Other causes
Risk group 4:
0.0810.65 (0.40 to 1.05)0.2310.76 (0.49 to 1.19)0.8351.04 (0.73 to 1.48)43/389 (11.1)102/817 (12.5)Prostate cancer
0.0870.61 (0.35 to 1.07)0.3620.77 (0.45 to 1.34)0.0890.71 (0.48 to 1.05)40/389 (10.3)65/817 (8.0)Other causes
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Table 4| Mortality figures and subdistribution hazard ratios (sHR) for radiotherapy versus radical prostatectomy for deaths from prostate
cancer and other causes after propensity score matching, stratified by risk group
P value
sHR (95% CI): radiotherapy v
surgery
No of events/Total No (%)
Type of mortality
No (%) of
non-matches†
Initial group sizes*Risk
categories SurgeryRadiotherapySurgeryRadiotherapy
0.1231.62 (0.88 to 3.01)17/2691 (0.6)27/2691 (1.0)Prostate cancer271 (9.1)97652962Group 1
0.0261.27 (1.03 to 1.57)156/2691 (5.8)191/2691 (7.1)Other causes
<0.0011.78 (1.29 to 2.47)57/3177 (1.8)103/3177 (3.2)Prostate cancer752 (19.1)79503929Group 2
<0.0011.41 (1.17 to 1.70)188/3177 (5.9)264/3177 (8.3)Other causes
0.0021.52 (1.17 to 1.98)91/1820 (5.0)136/1820 (7.5)Prostate cancer688 (27.4)25084923Group 3
0.1651.19 (0.93 to 1.54)112/1820 (6.2)131/1820 (7.2)Other causes
<0.0011.48 (1.22 to 1.78)182/7827 (2.3)264/7827 (3.4)Prostate cancer3987 (33.7)20 22311 814Non-metastatic
(groups 1-3)
<0.0011.31 (1.16 to 1.48)467/7827 (6.0)594/7827 (7.6)Other causes
0.5740.85 (0.48 to 1.50)25/219 (11.4)22/219 (10.0)Prostate cancer138 (38.7)357791Group 4
0.9971.00 (0.52 to 1.94)17/219 (7.8)17/219 (7.8)Other causes
*Treatment groups were matched 1:1in each risk group.
†Excluded from analysis.
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Table 5| Required effect (subdivision hazard ratio, sHR) of hypothetical unmeasured confounder to give observed propensity score adjusted
sHR of radiotherapy versus radical prostatectomy assuming no difference between cancer treatments
Assumed prevalence (%) of unmeasured confounder in radiotherapy cohort
Assumed prevalence (%) of
unmeasured confounder in
surgery cohort
Propensity score
adjusted sHR (95%CI)
Risk
categories
90705030
Required confounder sHR to produce observed radiotherapy v surgery sHR
2.292.793.959.37101.91 (1.16 to 3.14)Group 1
3.798.19Not possible—30
Not possibleNot possible——50
Not possible———70
2.072.483.407.30101.77 (1.37 to 2.29)Group 2
3.105.60Not possible—30
58.15Not possible——50
Not possible———70
1.671.912.434.32101.50 (1.19 to 1.88)Group 3
2.112.9910.92—30
4.32Not possible——50
Not possible———70
2.052.453.347.12101.76 (1.49 to 2.08)Non-metastatic
(groups 1-3)
3.045.41Not possible—30
38.59Not possible——50
Not possible———70
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Figures
Fig 1 Cumulative incidence function estimates of cancer specific and other cause mortality survival curves (n=34 515),
stratified according to treatment type
Fig 2 Forest plot depicting propensity score adjusted subdistribution hazard ratios (sHR) for radiotherapy versus radical
prostatectomy for cancer specific mortality stratified by risk group, and substratified by age and Charlson comorbidity index
score
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